How to buy Abbott Laboratories shares | $102.36

Own Abbott Laboratories shares in just a few minutes.

Fact checked

Abbott Laboratories (ABT) is a leading medical devices business based in the US. It opened the day at $104.89 after a previous close of $104.76. During the day the price has varied from a low of $102.23 to a high of $104.99. The latest price was $102.36 (25 minute delay). Abbott Laboratories is listed on the NYSE and employs 107,000 staff. All prices are listed in US Dollars.

How to buy shares in Abbott Laboratories

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ABT in this case.
  5. Research Abbott Laboratories shares. The platform should provide the latest information available.
  6. Buy your Abbott Laboratories shares. It's that simple.

How has Coronavirus impacted Abbott Laboratories's share price?

Since the stock market crash in March caused by coronavirus, Abbott Laboratories's share price has had significant positive movement.

Its last market close was $102.73, which is 14.87% up on its pre-crash value of $87.45 and 66.74% up on the lowest point reached during the March crash when the shares fell as low as $61.61.

If you had bought $1,000 worth of Abbott Laboratories shares at the start of February 2020, those shares would have been worth $721.80 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,180.37.

Abbott Laboratories share price

Use our graph to track the performance of ABT stocks over time.

Abbott Laboratories shares at a glance

Information last updated 2020-09-23.
Open$104.89
High$104.99
Low$102.23
Close$102.36
Previous close$104.76
Change $-2.4
Change % -2.291%
Volume 2,492,814
Information last updated 2020-09-20.
52-week range$61.61 - $114.195
50-day moving average $103.7021
200-day moving average $92.6192
Wall St. target price$115
PE ratio 62.0116
Dividend yield $1.44 (1.35%)
Earnings per share (TTM) $1.731
Promoted
eToro Free Stocks

Invest in Abbott Laboratories shares with 0% commission

Other fees may apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • If your trades get copied you can earn extra money
  • Create an account today in a few minutes

Share dealing platform comparison

Table: sorted by promoted deals first
Data indicated here is updated regularly
Name Product Price per trade Frequent trader rate Platform fees Brand description
Fineco
£2.95
£2.95
Zero platform fee
Fineco Bank is good for share traders and investors looking for a complete platform and wide offer. Your first 50 trades are free with Fineco, until 30/09/2020. T&Cs apply. Capital at risk.
IG
0% commission on US shares, and £3 on UK shares
From £5
£0 - £24 per quarter
IG is good for experienced traders, and offers learning resources for beginners, all with wide access to shares, ETFs and funds. Capital at risk.
Hargreaves Lansdown Fund and Share Account
£11.95
£5.95
No fees
Hargreaves Lansdown is the UK's number one platform for private investors, with the depth of features you'd expect from an established platform. Capital at risk.
eToro Free Stocks
0% commission, no markup, no ticket fee, no management fee
N/A
Withdrawal fee & GDP to USD deposit conversion
Capital at risk. 0% commission but other fees may apply.
Interactive Investor
From £7.99 on the Investor Service Plan
From £7.99 on the Investor Service Plan
No transfer fees or exit fees. £9.99 a month on the Investor Service Plan
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum deposit Maximum annual fee Price per trade Brand description
Moneyfarm stocks and shares ISA
£1500
0.75%
£0
Hargreaves Lansdown stocks and shares ISA
£100
0.45%
£11.95
Hargreaves Lansdown is the UK's biggest wealth manager. It's got everything you'll need, from beginners to experienced investors. Capital at risk.
Interactive Investor stocks and shares ISA
Any lump sum or £25 a month
£119.88
£7.99
Interactive Investor offers everything most investors need. Its flat fees makes it pricey for small portfolios, but cheap for big ones. Capital at risk.
Saxo Markets stocks and shares ISA
No minimum deposit requirement
0.12%
£8.00
Saxo Markets offers a wide access to a range of stocks, ETFs and funds. Capital at risk.
AJ Bell stocks and shares ISA
£500
0.25%
£9.95
AJ Bell is a good all-rounder for people who to choose between shares, funds, ISAs and pensions. Capital at risk.
Fidelity stocks and shares ISA
£1000 or a regular savings plan from £50
0.35%
£10.00
Fidelity is another good all-rounder, offering a good package at a decent price. Not suited for trading shares. Capital at risk.
Nutmeg stocks and shares ISA
£100
0.75%
£0
Nutmeg offers three types of portfolios. Choose the one that goes with your investment style. Capital at risk.
loading

Compare up to 4 providers

Data indicated here is updated regularly
Name Product Minimum investment Choose from Annual fee Brand description
Moneyfarm Pension
£1,500 (initial investment)
7 funds
0.35%-0.75%
Moneyfarm has pensions that are matched against your risk appetite, goals and planned retirement date. Capital at risk.
PensionBee Pension
No minimum
7 funds
0.5% - 0.95%
Pension Bee is a newbie in the pension market. It helps consolidate your pension plans into one place. Capital at risk.
Hargreaves Lansdown Pension
£100 or £25 a month
2,500 funds
0-0.45%
Hargreaves Lansdown is the UK's biggest wealth manager. It's got three different retirement options. Capital at risk.
Interactive Investor Pension
Any lump sum or £25 a month
Over 3,000 funds
£10/month
interactive investor is a flat-fee platform, which makes it cost effective for larger portfolios. Capital at risk.
Saxo Markets Pension
Saxo Markets Pension
£10
Over 11,000 funds
No annual fee
Saxo Markets gives flexibility and control over your investment strategy. Capital at risk.
AJ Bell Pension
£1,000
Over 2,000 funds
0.05-0.25%
AJ Bell has two different pension options, a self managed pension and one that is managed for you. Capital at risk.
Moneybox Pension
£1
3 funds
0.15% - 0.45% charged monthly
Manage your money with an easy-to-use Moneybox app. Capital at risk.
loading

Compare up to 4 providers

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.

Is it a good time to buy Abbott Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Abbott Laboratories price performance over time

Historical closes compared with the last close of $102.36

1 week (2020-09-14) -3.15%
1 month (2020-08-24) 0.96%
3 months (2020-06-24) 17.25%
6 months (2020-03-24) 46.88%
1 year (2019-09-20) 22.47%
2 years (2018-09-21) 48.24%
3 years (2017-09-21) 99.03%
5 years (2015-09-21) 136.40%

Is Abbott Laboratories under- or over-valued?

Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Abbott Laboratories's P/E ratio

Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 62x. In other words, Abbott Laboratories shares trade at around 62x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Abbott Laboratories's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.

Abbott Laboratories's PEG ratio

Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.4436. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Abbott Laboratories's PEG ratio in relation to those of similar companies.

Abbott Laboratories's EBITDA

Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $7.6 billion (£5.9 billion).

The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure a its profitability.

To put Abbott Laboratories's EBITDA into context you can compare it against that of similar companies.

Abbott Laboratories financials

Revenue TTM $31.4 billion
Operating margin TTM 14%
Gross profit TTM $18.7 billion
Return on assets TTM 4.01%
Return on equity TTM 9.86%
Profit margin 9.89%
Book value $17.271
Market capitalisation $196.2 billion

TTM: trailing 12 months

How to short and sell Abbott Laboratories shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ABT.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 10.4 million Abbott Laboratories shares held short by investors – that's known as Abbott Laboratories's "short interest". This figure is 18.2% down from 12.7 million last month.

There are a few different ways that this level of interest in shorting Abbott Laboratories shares can be evaluated.

Abbott Laboratories's "short interest ratio" (SIR)

Abbott Laboratories's "short interest ratio" (SIR) is the quantity of Abbott Laboratories shares currently shorted divided by the average quantity of Abbott Laboratories shares traded daily (recently around 5.7 million). Abbott Laboratories's SIR currently stands at 1.82. In other words for every 100,000 Abbott Laboratories shares traded daily on the market, roughly 1820 shares are currently held short.

To gain some more context, you can compare Abbott Laboratories's short interest ratio against those of similar companies.

However Abbott Laboratories's short interest can also be evaluated against the total number of Abbott Laboratories shares, or, against the total number of tradable Abbott Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abbott Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Abbott Laboratories shares in existence, roughly 10 shares are currently held short) or 0.006% of the tradable shares (for every 100,000 tradable Abbott Laboratories shares, roughly 6 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abbott Laboratories.

Find out more about how you can short Abbott Laboratories stock.

Abbott Laboratories's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Abbott Laboratories's total ESG risk score

Total ESG risk: 33.33

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 33.33 (as at 08/01/2020) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

To gain some more context, you can compare Abbott Laboratories's total ESG risk score against those of similar companies.

Abbott Laboratories's environmental score

Environmental score: 3.98/100

Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Abbott Laboratories's social score

Social score: 20.71/100

Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Abbott Laboratories's governance score

Governance score: 14.13/100

Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Abbott Laboratories's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.

Wondering how that compares? Below are the controversy scores of similar companies.

Environmental, social, and governance (ESG) summary

Abbott Laboratories was last rated for ESG on: 2020-08-01.

Total ESG score 33.33
Total ESG percentile 60.7
Environmental score 3.98
Environmental score percentile 5
Social score 20.71
Social score percentile 5
Governance score 14.13
Governance score percentile 5
Level of controversy 3

Abbott Laboratories share dividends

79%

Dividend payout ratio: 79.07% of net profits

Recently Abbott Laboratories has paid out, on average, around 79.07% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.35% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 1.35% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $1.44 per share.

Abbott Laboratories's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Abbott Laboratories's most recent dividend payout was on 17 August 2020. The latest dividend was paid out to all shareholders who bought their shares by 14 July 2020 (the "ex-dividend date").

Abbott Laboratories's dividend payout ratio is perhaps best considered in relation to those of similar companies.

Have Abbott Laboratories's shares ever split?

Abbott Laboratories's shares were split on a 10000:4798 basis on 2 January 2013. So if you had owned 4798 shares the day before before the split, the next day you'd have owned 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.

Abbott Laboratories share price volatility

Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as $61.61 up to $114.195. A popular way to gauge a stock's volatility is its "beta".

ABT.US volatility(beta: 0.95)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.9521. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).

To put Abbott Laboratories's beta into context you can compare it against those of similar companies.

Abbott Laboratories overview

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site